Tacrolimus CYP3A5 Pharmacogenomics Dose Predictor

Predicts initial tacrolimus dose based on CYP3A5 genotype (*1 expressers vs *3 non-expressers), kidney vs liver transplant, and race-based metabolizer status to reduce time to therapeutic range.

Weight
Height
Clinical Guidance

BMI is a screening measure of body size, not a direct measure of body fat. The standard WHO categories are underweight (<18.5), normal (18.5–24.9), overweight (25–29.9), and obese (≥30).

BMI can overestimate body fat in athletes with high muscle mass and underestimate it in older adults with low muscle mass. Interpret it alongside waist circumference and clinical context rather than as a standalone diagnosis.

⚕ Clinical Disclaimer: These calculators are for educational and reference purposes only. Always verify results with qualified clinical judgment and current clinical guidelines. Do not use as a sole basis for medical decisions.
Advertisement

How It Works

Predicts initial tacrolimus dose based on CYP3A5 genotype (*1 expressers vs *3 non-expressers), kidney vs liver transplant, and race-based metabolizer status to reduce time to therapeutic range

Each component has a specific meaning:

  • CYP3A5 genotype — The cyp3a5 genotype recorded for the scenario being assessed.
  • Kidney vs liver transplant — The kidney vs liver transplant recorded for the scenario being assessed.
  • Race-based metabolizer status — The race-based metabolizer status recorded for the scenario being assessed.

Note: Interpret the tacrolimus pgx result against the thresholds and context described above.

How to Use

Enter the CYP3A5 genotype, kidney vs liver transplant, race-based metabolizer status for the scenario you are assessing. Predicts initial tacrolimus dose based on CYP3A5 genotype (*1 expressers vs *3 non-expressers), kidney vs liver transplant, and race-based metabolizer status to reduce time to therapeutic range. Use the tacrolimus pgx result to inform your calculation.

Frequently Asked Questions